Structural disease modification in axial spondyloarthritis.

Disease modification" in axial spondyloarthritis (axSpA) seeks to not only alleviate clinical symptoms but also alter the disease's natural course by impeding new bone formation. Recent years have witnessed the effectiveness of treatments, including biologics and nonsteroidal anti-inflammatory drugs, in managing axSpA symptoms. Emerging evidence points toward their potential impact on slowing structural disease progression. This comprehensive review centers on the pivotal role of inhibiting new bone formation in axSpA disease modification. It delves into the significance of imaging techniques for assessing disease progression and explores the disease-modifying properties of available axSpA treatments, encompassing NSAIDs, TNF inhibitors, IL-17 inhibitors, and JAK inhibitors. This article offers valuable insights into the evolving landscape of disease modification strategies in axial spondyloarthritis, highlighting the multifaceted approaches used to attain these objectives. Copyright © 2023 Elsevier Ltd. All rights reserved.

Citation

Brona Dinneen, Finbar O'Shea, Lianne Gensler. Structural disease modification in axial spondyloarthritis. Best practice & research. Clinical rheumatology. 2023 Sep;37(3):101898

Mesh Tags

Substances

PMID: 38042689

search → result